Makers of copycat drugs will face pressure to bring down prices even more quickly as the U.S.Food and Drug Administration pushes to get more low-costcompetition to market.
The FDA wants to prioritize certain generic-drug applications inan effort to drive down prices, which have drawn increasingscrutiny from lawmakers and the ire of President Donald Trump. The agency hasits sights set on an incentive granted to drugmakers that are first to seek approval fora copy of a brand-name drug, according to a policy documentreleased Thursday.
Generic-drug makers must submit their medicines to the FDA forapproval. So-called first filers are typically able to sell theirversion of a brand-name drug free from competition from othergenerics for 180 days. When that period is up, the floodgates open-- though a backlog of applications awaiting FDA clearance hasmeant some first filers have had the market to themselves for farlonger.
Continue Reading for Free
Register and gain access to:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
